Yousif Capital Management LLC Sells 19,936 Shares of Pfizer Inc. $PFE

Yousif Capital Management LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 3.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 619,842 shares of the biopharmaceutical company’s stock after selling 19,936 shares during the period. Yousif Capital Management LLC’s holdings in Pfizer were worth $15,794,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Ridgecrest Wealth Partners LLC lifted its holdings in Pfizer by 1.7% during the 3rd quarter. Ridgecrest Wealth Partners LLC now owns 28,502 shares of the biopharmaceutical company’s stock valued at $726,000 after purchasing an additional 480 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Pfizer by 3.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 140,222 shares of the biopharmaceutical company’s stock worth $3,573,000 after buying an additional 4,723 shares during the period. Foundation Resource Management Inc. grew its stake in Pfizer by 1.2% in the 3rd quarter. Foundation Resource Management Inc. now owns 903,641 shares of the biopharmaceutical company’s stock valued at $23,025,000 after buying an additional 10,867 shares during the last quarter. HBK Sorce Advisory LLC raised its holdings in Pfizer by 16.4% in the 3rd quarter. HBK Sorce Advisory LLC now owns 177,076 shares of the biopharmaceutical company’s stock valued at $4,547,000 after acquiring an additional 25,013 shares during the period. Finally, Cohen Investment Advisors LLC lifted its position in Pfizer by 9.9% during the third quarter. Cohen Investment Advisors LLC now owns 113,775 shares of the biopharmaceutical company’s stock worth $2,899,000 after acquiring an additional 10,285 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $25.23 on Tuesday. The company has a market cap of $143.43 billion, a price-to-earnings ratio of 14.67 and a beta of 0.46. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a fifty day moving average price of $25.11 and a 200-day moving average price of $24.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio is 100.00%.

Analysts Set New Price Targets

PFE has been the topic of several research reports. Bank of America lowered their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.